The first step in O-linked oligosaccharide synthesis is adding a N-acetylgalactosamine to serine or threonine resulting in the formation of the Tn antigen and Tn antigen can be proceed along different pathways through different glycosylation processes. The galactose can be added on Tn antigen by a β1,3-galactosyltransferase results in the formation of the Thomsen-Friedenreich antigen (Galβ1,3GalNAcα-O-Ser/Thr) also known as Thomsen–Friedenreich (T or TF) antigen or CD176. The patents with Tn syndrome are β1,3-galactosyltransferase deficiention resulting in the expression of Tn antigen on their hematopoietic cells. Both antigens have been shown previously to correlate with various cancer types.

The abnormal protein glycosylation might associated with human cancer and the identification of protein glycoforms might be cancer biomarkers and therapeutic targets. Recently study find that the O-link glycan changes in some of the surface protein, for Ex, MUC1 and CD43, might also undergoing EMT and metastases activity.

arigo provides a T/Tn antigen antibody Duos, ARG30016, including antibodies reacting T antigen and Tn antigen for users to study the potentially glycol-structure and glycan changes of the target protein and it might be useful to findout the biomarker and therapeutic agent.